Shockwave Medical (NASDAQ:SWAV) reported Q1 EPS of $0.41, $0.23 better than the analyst estimate of $0.18. Revenue for the quarter came in at $93.6 million versus the consensus estimate of $86.41 million.
GUIDANCE:
Shockwave Medical sees Q2 2022 revenue of $435-455 million, versus the consensus of $417.9 million.